BIOMIND LABS INC. (F:3XI) — Market Cap & Net Worth
Market Cap & Net Worth: BIOMIND LABS INC. (3XI)
BIOMIND LABS INC. (F:3XI) has a market capitalization of $3.31 Million (€2.83 Million) as of July 22, 2026. Listed on the F stock exchange, this Germany-based company holds position #29316 globally and #2544 in its home market, demonstrating a -30.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOMIND LABS INC.'s stock price €0.04 by its total outstanding shares 77571773 (77.57 Million). Review BIOMIND LABS INC. free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
BIOMIND LABS INC. Market Cap History: 2021 to 2026
BIOMIND LABS INC.'s market capitalization history from 2021 to 2026. Data shows change from $83.43 Million to $3.31 Million (-53.39% CAGR).
BIOMIND LABS INC. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOMIND LABS INC.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 3XI by Market Capitalization
Companies near BIOMIND LABS INC. in the global market cap rankings as of July 22, 2026.
Key companies related to BIOMIND LABS INC. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #542 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $482.00 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $675.19 |
| #542 | Argen-X | BR:ARGX | $49.55 Billion | €760.20 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €243.90 |
BIOMIND LABS INC. Historical Marketcap From 2021 to 2026
Between 2021 and today, BIOMIND LABS INC.'s market cap moved from $83.43 Million to $ 3.31 Million, with a yearly change of -53.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.31 Million | -46.72% |
| 2025 | €6.21 Million | -75.88% |
| 2024 | €25.76 Million | +14100.00% |
| 2023 | €181.38K | -99.22% |
| 2022 | €23.40 Million | -71.96% |
| 2021 | €83.43 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 22nd, 2026 the market cap of BIOMIND LABS INC. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.31 Million USD |
| MoneyControl | $3.31 Million USD |
| MarketWatch | $3.31 Million USD |
| marketcap.company | $3.31 Million USD |
| Reuters | $3.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIOMIND LABS INC.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more